2-Dimethylaminoethanol
Scientific Name: DMAE
Other Names: 2-Dimethyl aminoethanol, Deaner, Deanol, Dimethylaminoethanol, Dimethylethanolamine
References
Alphs L, Davis JM. Noncatecholaminergic treatments of tardive dyskinesia. Journal of Clinical Psychopharmacology. 1982;2(6):380-385.
Amsterdam JD, Dubin W. Huntington's Chorea and dimethylaminoethanol (deanol). Journal of Clinical Psychiatry. 1978;39(7):626-628.
Casey DE. Mood alterations during deanol therapy. Psychopharmacology (Berlin). 1979;62(2):187-191.
Casey DE, Denny D. Deanol in the treatment of tardive dyskinesia. American Journal of Psychiatry. 1975;132(8):864-867.
Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berlin). 1977;54(1):1-8.
Ceder G, Dahlberg L, Schuberth J. Effects of 2-dimethylaminoethanol (deanol) on the metabolism of choline in plasma. Journal of Neurochemistry. 1978;30(6):1293-1296.
Curran DJ, Nagaswami S, Mohan KJ. Treatment of phenothiazine induced bulbar persistent dyskinesia with deanol acetamidobenzoate. Diseases of the Nervous System. 1975;36(2):71-73.
Davis KL, Hollister LE, Vento AL, Beilstein BA, Rosekind GR. Dimethylaminoethanol (deanol): effect on apomorphine-induced stereotypy and an animal model of tardive dyskinesia. Psychopharmacology (Berlin). 1979;63(2):143-146.
de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berlin). 1979;65(3):219-223.
Dimpfel W, Wedekind W, Keplinger I. Efficacy of dimethylaminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states. European Journal of Medical Research. 2003;8(5):183-191.
Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. Journal of the American Geriatric Society. 1977;25(6):241-244.
Fisher MC, Zeisel SH, Mar MH, Sadler TW. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology. 2001;64(2):114-122.
Fisher MC, Zeisel SH, Mar MH, Sadler TW. Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEB Journal. 2002;16(6):619-621.
Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. American Journal of Psychiatry. 1981;138(7):970-972.
Flood JF, Smith GE, Cherkin A. Memory retention: potentiation of cholinergic drug combinations in mice. Neurobiology and Aging. 1983;4(1):37-43.
Gragnani A, Giannoccaro FB, Sobral CS, et al. Dimethylaminoethanol affects the viability of human cultured fibroblasts. Aesthetic and Plastic Surgery. 2007;31(6):711-718.
Grossman R. The role of dimethylaminoethanol in cosmetic dermatology. American Journal of Clinical Dermatology. 2005;6(1):39-47.
Haubrich DR, Gerber NH, Pflueger AB. Deanol affects choline metabolism in peripheral tissues of mice. Journal of Neurochemistry. 1981;37(2):476-482.
Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? European Neurology. 1991;31(6):423-425.
Jameson HD, Blacker HM, Fuchs ME. Hemiballismus-hemichorea treated with dimethylaminoethanol. Diseases of the Nervous System. 1977;38(11):931-932.
Jope RS, Jenden DJ. Dimethylaminoethanol (deanol) metabolism in rat brain and its effect on acetylcholine synthesis. Journal of Pharmacology and Experimental Therapeutics. 1979;211(3):472-479.
Jus A, Villeneuve A, Gautier J, et al. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology. 1978;4(3):140-149.
Klawans HL, Topel JL, Bergen D. Deanol in the treatment of levodopa-induced dyskinesias. Neurology. 1975;25(3):290-293.
Klonne DR, Dodd DE, Pritts IM, et al. Dimethylethanolamine: acute, 2-week, and 13-week inhalation toxicity studies in rats. Fundamental and Applied Toxicology. 1987;9(3):512-521.
Kostopoulos GK, Phillis JW. The effects of dimethylaminoethanol (deanol) on cerebral cortical neurons. Psychopharmacology Communications. 1975;1(3):339-347.
Laifer S. DMAE. The smart supplement. Life Extension. November, 2004. 4 pages.
Leung H-W, Tyl RW, Ballantyne B, Klonne DR. Developmental toxicity study in fischer 344 rats by whole-body exposure to N,N-dimethylethanolamine vapor. Journal of Applied Toxicology. 1996;16(6):533-538.
Lewis JA, Lewis BS. Deanol in minimal brain dysfunction. Diseases of the Nervous System. 1977;38(12 Pt 2):21-24.
Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Clinical Pharmacology and Therapeutics. 1975;17(5):534-540.
Lindeboom SF, Lakke JP. Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurologica Scandanavia. 1978;58(2):134-138.
Lohr J, Acara M. Effect of dimethylaminoethanol, an inhibitor of betaine production, on the disposition of choline in the rat kidney. Journal of Pharmacology and Experimental Therapeutics. 1990;252(1):154-158.
Marsh GR, Linnoila M. The effects of deanol on cognitive performance and electrophysiology in elderly humans. Psychopharmacology (Berlin). 1979;66(1):99-104.
McGrath JJ, Soares KV. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Systematic Review. 2000;(2):CD000207.
Miller E. Dimethylaminoethanol in the treatment of blepharospasm New England Journal of Medicine. 1973;289:697.
Millington WR, McCall AL, Wurtman RJ. Deanol acetamidobenzoate inhibits the blood-brain barrier transport of choline. Annals of Neurology. 1978 Oct;4(4):302-306.
Moeckel GW, Lien YH. Distribution of de novo synthesized betaine in rat kidney: role of renal synthesis on medullary betaine accumulation. American Journal of Physiology. 1997;272(1 Pt 2):F94-F99.
Morissette G, Germain L, Marceau F. The antiwrinkle effect of topical concentrated 2-dimethylaminoethanol involves a vacuolar cytopathology. British Journal of Dermatology. 2007;156(3):433-439.
Natural Medicines Comprehensive Database, Online Edition. Pharmacist's Letter/Prescriber's Letter. Stockton CA: Therapeutic Research Facility, 2006.
Available at: http://www.pharmacistsletter.com/(S(ulqz3s45omt3ag5 5um4kj345))/home.aspx?li=1&st=1&cs=&s=ND.
Pa ge EH, Cook CK, Hater MA, Mueller CA, Grote AA, Mortimer VD. Visual and ocular changes associated with exposure to two tertiary amines. Occupational and Environmental Medicine. 2003;60(1):69-75.
Penovich P, Morgan JP, Kerzner B, Karch F, Goldblatt D. Double-blind evaluation of deanol in tardive dyskinesia. Journal of the American Medical Association. 1978;239(19):1997-1998.
Peterson LA, Sharabi FM, Long JP, Taylor CA Jr, Barfknecht CF. The antagonism of nicotine-induced cardiovascular responses by DMAE and DEO analogs. European Journal of Pharmacology. 1976;37(2):303-310.
Pinta ER. Deanol in Gilles de la Tourette Syndrome: a preliminary investigation. Diseases of the Nervous System. 1977;38(3):214-215.
Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. Journal of Child Neurology. 1988;3 (Suppl):S68-S72.
Rosen MA, Jones RM, Yano Y, Budinger TF. Carbon-11 choline: synthesis, purification, and brain uptake inhibition by 2-dimethylaminoethanol. Journal of Nuclear Medicine. 1985;26(12):1424-1428.
Sergio W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Medical Hypotheses. 1988;26(4):255-257.
Siegers CP, Younes M. Influence of 2-dimethylaminoethanol on the hepatotoxicity of paracetamol in rats and mice. [Article in German] Arzneimittelforschung. 1979;29(3):520-523.
Simpson GM, Voitashevsky A, Young MA, Lee JH. Deanol in the treatment of tardive dyskinesia. Psychopharmacology (Berlin). 1977;52(3):257-261.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia--a systematic review and meta-analysis. Schizophrenia Research. 1999;39(1):1-18.
Stafford JR, Fann WE. Deanol acetamidobenzoate (Deaner) in tardive dyskinesia. Diseases of the Nervous System. 1977;38(12 Pt 2):3-6.
Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Progress in Neuropsychopharmacology, Biology and Psychiatry. 2004;28(7):1099-1107.
Tamminga CA, Smith RC, Ericksen SE, Chang S, Davis JM. Cholinergic influences in tardive dyskinesia. American Journal of Psychiatry. 1977;134(7):769-774.
Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Archives of Neurology. 1977;34(12):756-758.
Taylor P, Brown JH. Acetylcholine. In: Siegel GJ, Agranoff BW, Fisher SK, Albers RW, Uhler MD, eds. Basic Neurochemistry. Molecular, Cellular and Medical Aspects. Sixth Edition. Philadelphia; Lippincott Williams and Wilkins: 1999.
Tegeler J, Woller W. Therapeutic measures in tardive dyskinesia. [Article in German] Fortschr Neurol Psychiatr. 1983;51(6):203-226.
Uhoda I, Faska N, Robert C, Cauwenbergh G, Pierard GE. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Research Technology. 2002;8(3):164-167.
Waite KA, Vance DE. Dimethylethanolamine does not prevent liver failure in phosphatidylethanolamine N-methyltransferase-deficient mice fed a choline-deficient diet. Biochimica at Biophysica Acta. 2004;1636(2-3):175-182.
Zahniser NR, Chou D, Hanin I. Is 2-dimethylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation. Journal of Pharmacology and Experimental Therapeutics. 1977;200(3):545-559.
Updated July 18, 2008
|
References 
